

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM532701

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Ablacon Inc.		07/18/2019	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Venture Lending & Leasing IX, Inc.		
<b>Street Address:</b>	104 La Mesa Drive, Suite 102		
<b>City:</b>	Portola Valley		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94028		
<b>Entity Type:</b>	Corporation: MARYLAND		
<b>Name:</b>	Venture Lending & Leasing VIII, Inc.		
<b>Street Address:</b>	104 La Mesa Drive, Suite 102		
<b>City:</b>	Portola Valley		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94028		
<b>Entity Type:</b>	Corporation: MARYLAND		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	87440139	EGF	
<b>Serial Number:</b>	87839825	ABLACLOUD	
<b>Serial Number:</b>	88214906	AF WATCH	
<b>Serial Number:</b>	88214967	ABLACHAIN	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4157774961		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	415 981 1400		
<b>Email:</b>	nsust@greeneradovsky.com		
<b>Correspondent Name:</b>	JEFFREY T. KLUGMAN		
<b>Address Line 1:</b>	FOUR EMBARCADERO CENTER, SUITE 4000		
<b>Address Line 4:</b>	SAN FRANCISCO, CALIFORNIA 94111		

OP \$115.00 87440139

<b>NAME OF SUBMITTER:</b>	JEFFREY T. KLUGMAN
<b>SIGNATURE:</b>	/JEFFREY T. KLUGMAN/
<b>DATE SIGNED:</b>	07/19/2019
<b>Total Attachments: 11</b> source=Ablacon Inc. 89-0507 IPSA#page1.tif source=Ablacon Inc. 89-0507 IPSA#page2.tif source=Ablacon Inc. 89-0507 IPSA#page3.tif source=Ablacon Inc. 89-0507 IPSA#page4.tif source=Ablacon Inc. 89-0507 IPSA#page5.tif source=Ablacon Inc. 89-0507 IPSA#page6.tif source=Ablacon Inc. 89-0507 IPSA#page7.tif source=Ablacon Inc. 89-0507 IPSA#page8.tif source=Ablacon Inc. 89-0507 IPSA#page9.tif source=Ablacon Inc. 89-0507 IPSA#page10.tif source=Ablacon Inc. 89-0507 IPSA#page11.tif	

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is made as of July 18, 2019, between ABLACON INC., a Delaware corporation ("Grantor"), and VENTURE LENDING & LEASING VIII, INC. ("VLL8") and VENTURE LENDING & LEASING IX, INC. ("VLL9"), both Maryland corporations (sometimes referred to herein individually and together as "Secured Party").

### RECITALS

A. Pursuant to that certain Loan and Security Agreement of even date herewith between Grantor, as borrower, and Secured Party, as lender (as amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), Secured Party has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in the Loan Agreement. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Loan Agreement.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in substantially all of Grantor's personal property whether presently existing or hereafter acquired. To that end, Grantor has executed in favor of Secured Party the Loan Agreement granting a security interest in all Collateral, and is executing this Agreement with respect to certain items of Intellectual Property, in particular.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Obligations, Grantor hereby grants a security interest to Secured Party, as security, in and to Grantor's entire right, title and interest in, to and under the following Intellectual Property, now owned or hereafter acquired by Grantor or in which Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the "Collateral" for purposes of this Agreement):

(a) Any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) All letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(c) All trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, and reissues,

extensions or renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(d) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing the term "Collateral" shall not include: (a) "intent-to-use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such "intent to use" trademarks would be contrary to applicable law or (b) any contract, instrument or chattel paper in which Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the term "Collateral" shall include, and Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party's unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper.

2. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor has rights (as defined in the UCC) in the Collateral, except for Permitted Liens;

(b) During the term of this Agreement, Grantor will not transfer or otherwise encumber any interest in the Collateral, except for Permitted Liens and except for transfers otherwise permitted under the Loan Agreement;

(c) To its knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Collateral violates the rights of any third party;

(d) Grantor shall deliver to Secured Party within thirty (30) days of the last day of each fiscal quarter, a report signed by Grantor, in form reasonably acceptable to Secured Party, listing (i) any

applications or registrations that Grantor has made or filed in respect of any patents, copyrights or trademarks, (ii) the status of any outstanding applications or registrations and (iii) any material change in the composition of the Collateral;

(e) Grantor shall use reasonable commercial efforts to (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights, (ii) detect infringements of the Trademarks, Patents and Copyrights and promptly advise Secured Party in writing of material infringements detected, and (iii) not allow any material Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public unless Grantor deems it to be in the best interest of Grantor's business;

(f) Grantor shall apply for registration (to the extent not already registered) with the United States Patent and Trademark Office or the United States Copyright Office, as applicable: (i) those intellectual property rights listed on Exhibits A, B and C hereto within thirty (30) days of the date of this Agreement; and (ii) those additional intellectual property rights developed or acquired by Grantor from time to time in connection with any product or service, prior to the sale or licensing of such product or the rendering of such service to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B and C), except, in each case, with respect to such rights that Grantor determines in its sole but reasonable commercial judgment need not be registered to protect its own business interests. Grantor shall, from time to time, execute and file such other instruments, and take such further actions as Secured Party may reasonably request from time to time to perfect or continue the perfection of Secured Party's interest in the Collateral; and

(g) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Secured Party's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interests in any property included within the definition of the Collateral acquired under such contracts, except for provisions in such material contracts as are referenced in the last paragraph of Section 1 of this Agreement.

### 3. Further Assurances: Attorney in Fact.

(a) On a continuing basis, Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by Secured Party, to perfect Secured Party's security interest in all Copyrights, Patents and Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all Collateral.

(b) Grantor hereby irrevocably appoints Secured Party as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time in Secured Party's discretion, to take any action and to execute any instrument which Secured Party may deem necessary or advisable to accomplish the purposes of this Agreement, including (i) to modify, in its sole discretion, this Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibits A, B and C, hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest, (ii) to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Grantor where permitted by law, and (iii) after the occurrence and during the continuance of an Event of Default, to transfer the Collateral into the name of Secured Party or a third party to the extent permitted under the California Uniform Commercial Code.

4. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Agreement:

(a) An Event of Default under the Loan Agreement; or

(b) Grantor breaches in any material respect any warranty or agreement made by Grantor in this Agreement and, as to any breach that is capable of cure, Grantor fails to cure such breach within thirty (30) days of the sooner to occur of Grantor's receipt of notice of such breach from Secured Party or the date on which such breach first becomes known to Grantor.

5. Amendments. This Agreement may be amended only by a written instrument signed by both parties hereto, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.

6. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. This Agreement may be executed by electronic signatures. Grantor and Secured Party expressly agree to conduct the transactions contemplated by this Agreement by electronic means (including, without limitation, with respect to the execution, delivery, storage and transfer of this Agreement by electronic means and to the enforceability of electronic Loan Documents). Delivery of an executed signature page to this Agreement by facsimile or other electronic mail transmission shall be effective as delivery of a manually executed counterpart hereof.

7. Several Nature of Secured Party's Obligations and Rights; Pari Passu Security Interests. This Agreement is and shall be interpreted for all purposes as separate and distinct agreements between Grantor and VLL8, on the one hand, and Grantor and VLL9, on the other hand, and nothing in this Agreement shall be deemed a joint venture, partnership or other association between VLL8 and VLL9. Each reference in this Agreement to "Secured Party" shall mean and refer to each of VLL8 and VLL9, singly and independent of one another. Without limiting the generality of the foregoing, the covenants and other obligations of "Secured Party" under this Agreement are several and not joint obligations of VLL8 and VLL9, and all rights and remedies of "Secured Party" under this Agreement may be exercised by VLL8 and/or VLL9 independently of one another. The security interests granted by Grantor to each of VLL8 and VLL9 hereunder and under the Loan Agreement shall be deemed to have been granted and perfected at the same time and shall be of equal priority.

*[Signature Pages Follow]*

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

**GRANTOR:**

ABLACON INC.

By: DK  
Name: Doug Koo  
Title: CFO

Address for Notices:

400 Concar Dr.  
San Mateo, CA 94402  
Attn: CFO  
Fax #: 6506788918  
Phone #: 6506788918

**SECURED PARTY:**

VENTURE LENDING & LEASING VIII, INC.

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

Address for Notices:

104 La Mesa Dr., Suite 102  
Portola Valley, CA 94028  
Attn: Chief Financial Officer  
Fax # 650-234-4343  
Phone # 650-234-4300

**SECURED PARTY:**

VENTURE LENDING & LEASING IX, INC.

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

Address for Notices:

104 La Mesa Dr., Suite 102  
Portola Valley, CA 94028  
Attn: Chief Financial Officer  
Fax # 650-234-4343  
Phone # 650-234-4300

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

**GRANTOR:**

ABLACON INC.

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

Address for Notices:

\_\_\_\_\_  
\_\_\_\_\_

Attn: \_\_\_\_\_  
Fax #: \_\_\_\_\_  
Phone #: \_\_\_\_\_

**SECURED PARTY:**

VENTURE LENDING & LEASING VIII, INC.

By: \_\_\_\_\_  
Name: David Wanek  
Title: Vice President

Address for Notices:

104 La Mesa Dr., Suite 102  
Portola Valley, CA 94028  
Attn: Chief Financial Officer  
Fax # 650-234-4343  
Phone # 650-234-4300

**SECURED PARTY:**

VENTURE LENDING & LEASING IX, INC.

By: \_\_\_\_\_  
Name: David Wanek  
Title: Vice President

Address for Notices:

104 La Mesa Dr., Suite 102  
Portola Valley, CA 94028  
Attn: Chief Financial Officer  
Fax # 650-234-4343  
Phone # 650-234-4300



EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

<u>Description:</u>	<u>Registration/Application Number:</u>	<u>Registration/Application Date:</u>
Elongated Medical Device Suitable For Intravascular Insertion, Optical Force Sensing Assembly For An Elongated Medical Device And Method Of Making A Medical Optical Force Sensing Assembly	International PCT/EP2015/001097 WO 2016192741	Dec 8, 2016 May 29, 2015
Optical Force Sensing Assembly for an Elongated Medical Device	U.S. 15/577,924 2018/0161119	November 29, 2017 / June 14, 2018
Elongated Medical Device Suitable For Intravascular Insertion, Optical Force Sensing Assembly For An Elongated Medical Device And Method Of Making A Medical Optical Force Sensing Assembly	EP EP15736393.8 EP3304017 (A1)	April 11, 2018 May 29, 2015
Elongated Medical Device Suitable For Intravascular Insertion, Optical Force Sensing Assembly For An Elongated Medical Device And Method Of Making A Medical Optical Force Sensing Assembly	International PCT/EP2016/000870 WO 2016192841	Dec 8, 2016 May 25, 2016
Elongated Medical Device Suitable for Intravascular Insertion and Method of Making an Elongated Medical Device Suitable for Intravascular Insertion	International PCT/EP2015/001801	September 7, 2015
System For Analyzing Electrophysiological Data And Method For Analyzing Electrophysiological Data	International PCT/EP2016/001515 WO 2017/041892	March 16, 2017 September 7, 2016
System For Analyzing Electrophysiological Data And Method For Analyzing Electrophysiological Data	U.S. 15/756,865 2018/0279896	October 4, 2018 March 1, 2018
System For Analyzing Electrophysiological Data And Method For Analyzing Electrophysiological Data	EP EP16763726.3 EP 3346914	July 18, 2018 September 7, 2016
Elongated Medical Device Suitable For Intravascular Insertion And Method Of Making An Elongated Medical Device Suitable For Intravascular Insertion	International PCT/EP2016/001513 WO 2017/041890	March 16, 2017 September 7, 2016

Systems, Devices, Components And Methods For Detecting The Locations Of Sources Of Cardiac Rhythm Disorders In A Patient's Heart	International PCT/IB2016/001273 WO 2017/042623	March 16, 2017 September 7, 2016
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart	U.S. 15/548,671 U.S. 2018/0020916 U.S. Patent No. 10,201,277	January 25, 2018 February 12, 2019 August 3, 2017
Systems, Devices, Components And Methods For Detecting The Locations Of Sources Of Cardiac Rhythm Disorders In A Patient's Heart	EP 16843733.3 EP 3346915	July 18, 2018 September 7, 2016
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart	U.S. 15/258,410 U.S. 2017/0065198 U.S. Patent No. 10,143,374	September 7, 2016 March 9, 2017 December 4, 2018
Elongated Medical Device Suitable for Intravascular Insertion and Method of Making an Elongated Medical Device Suitable for Intravascular Insertion	International PCT/EP2015/001802	September 7, 2015
Elongated Medical Device Suitable For Intravascular Insertion And Method Of Making An Elongated Medical Device Suitable For Intravascular Insertion	International PCT/EP2016/001512 WO 2017/041889	September 7, 2016 March 16, 2017
Elongated Medical Device Suitable For Intravascular Insertion	International PCT/EP2015/001803	September 7, 2015
Elongated Medical Device Suitable For Intravascular Insertion And Method Of Making An Elongated Medical Device Suitable For Intravascular Insertion	International PCT/EP2016/001512 WO 2017/041889	September 7, 2016 March 16, 2017
Elongated Medical Device Suitable For Intravascular Insertion	International PCT/EP2016/001514 WO 2017/041891	September 7, 2016 March 16, 2017
Medical System For Mapping of Action Potential Data	International PCT/EP2016/000087 WO 2017/125114	January 19, 2016 July 27, 2017
Medical System For Mapping of Action Potential Data	EP 20160703057 EP 3405094	January 19, 2016 November 28, 2018
Elongated Medical Device Suitable for Intravascular Insertion and Method Of Making Such a Device	EP 16196472.1 EP3315086 (A1)	October 28, 2016 May 2, 2018
Electrophysiological Mapping Catheter	U.S. 62/414,183	October 28, 2016
Electrophysiological Mapping Catheter	U.S. 15/793,594 U.S. 2018/0116595	October 25, 2017 May 3, 2018

Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart Using Optical Flow	U.S. 62/473,137	March 17, 2017
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart and Classifying Same	U.S. 62/486,387	April 17, 2017
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart and Classifying Same	U.S. 15/923,286	March 17, 2018
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart and Classifying Same	EP 18162169.9 EP 3375365	March 16, 2018 September 19, 2018
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart, Electrophysiological Mapping Catheters, Electrophysiological Mapping Stamp Catheters, Force Sensing Ablation Catheters, Coronary Sinus Navigation Catheters, Catheter Co-Localization Systems and Devices, and AF Therapy Guidance Cloud Computing and Analysis Systems	U.S. 62/659,513	April 18, 2018
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart	U.S. 62/784,605	December 24, 2018
Electrophysiological Mapping Catheter	U.S. 62/770,697	November 21, 2018
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart	U.S. 16/231,883	December 24, 2018
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart	U.S. 16/168,235	October 23, 2018
Multiple Configuration Electrophysiological Mapping Catheter, and Systems, Devices, Components and Methods Associated Therewith	U.S. 16/156,637	October 10, 2018
Medical System for Mapping of Action Potential Data	U.S. 16/071,387 July 19, 2018	Published by WIPO as a PCT

## EXHIBIT C

## Trademarks

Description:	Registration/Application Number:	Jurisdiction:	Registration/Application Date:
ABLAACON	4986017	US	June 28, 2016
ABLAACON	013895941	EM (European Community)	March 27, 2015
ABLAACON	1277374	WO	September 10, 2015
ABLAACON	682116	CH	September 9, 2015
ABLAACON	G1277374	CN	December 10, 2015
ABLAASENSE	682117	CH	September 9, 2015
ABLAASENSE	4986018	US	June 28, 2016
ABLAASENSE	013901079	EM (European Community)	March 27, 2015
ABLAASENSE	G1277375	CN	December 10, 2015
ABLAASENSE	1277375	WO	September 10, 2015
ABLAJECT	013901087	EM (European Community)	March 27, 2015
ABLAJECT	4986019	US	June 28, 2016
ABLAJECT	1277376	WO	September 10, 2015
ABLAJECT	682118	CH	September 9, 2015
ABLAJECT	G1277376	CN	December 10, 2015
ABLAMAP	4986020	US	June 28, 2016
ABLAMAP	682119	CH	September 9, 2015
ABLAMAP	1277377	WO	September 10, 2015
ABLAMAP	013901095	EM (European Community)	March 27, 2015
ABLAMAP	G1277377	CN	September 10, 2015
EGF	87440139	US	May 8, 2017
ABLACLOUD	87839825	US	March 19, 2018
AF WATCH	88214906	US	December 3, 2018
ABLACHAIN	88214967	US	December 3, 2018

49013/0607  
JTK/551010.2